Passage Bio, Inc.
PASG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $4 | $0 | $0 |
| Gross Profit | $0 | -$4 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $40 | $60 | $86 | $118 |
| G&A Expenses | $25 | $42 | $49 | $60 |
| SG&A Expenses | $25 | $42 | $49 | $60 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | -$5 | $3 | $8 |
| Operating Expenses | $70 | $96 | $138 | $186 |
| Operating Income | -$70 | -$100 | -$138 | -$186 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6 | -$2 | $2 | $0 |
| Pre-Tax Income | -$65 | -$102 | -$136 | -$185 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$65 | -$102 | -$136 | -$185 |
| % Margin | – | – | – | – |
| EPS | -21.44 | -37.29 | -50 | -69.51 |
| % Growth | 42.5% | 25.4% | 28.1% | – |
| EPS Diluted | -21.44 | -37.29 | -50 | -69.51 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $6 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $4 | $4 | $2 |
| EBITDA | -$62 | -$98 | -$132 | -$176 |
| % Margin | – | – | – | – |